Sanofi MS drug from Genzyme shines, US skin unit to be sold?

Genzyme Corp has presented more promising data on its investigational multiple sclerosis treatment alemtuzumab, a drug which played a pivotal role in the firm getting a higher price from acquirer Sanofi-Aventis. In February, the French drugmaker upped its $18.50 billion offer to $20.1 billion and also agreed a tradable 'contingent value right', entitling Genzyme shareholders to payments linked to the success of alemtuzumab, which will be sold as Lemtrada, for MS; it is already approved, as

Read more ...